Noesis Capital Mangement Corp Reduces Position in Abbott Laboratories $ABT

Noesis Capital Mangement Corp lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 7.3% during the 2nd quarter, Holdings Channel reports. The firm owned 2,139 shares of the healthcare product maker’s stock after selling 168 shares during the quarter. Noesis Capital Mangement Corp’s holdings in Abbott Laboratories were worth $291,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of ABT. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the last quarter. Rossby Financial LCC purchased a new stake in shares of Abbott Laboratories in the 1st quarter valued at $35,000. Arbor Trust Wealth Advisors LLC boosted its holdings in shares of Abbott Laboratories by 0.5% in the 1st quarter. Arbor Trust Wealth Advisors LLC now owns 47,381 shares of the healthcare product maker’s stock valued at $6,285,000 after acquiring an additional 226 shares during the last quarter. Keybank National Association OH boosted its holdings in shares of Abbott Laboratories by 36.1% in the 1st quarter. Keybank National Association OH now owns 1,325,495 shares of the healthcare product maker’s stock valued at $175,827,000 after acquiring an additional 351,431 shares during the last quarter. Finally, LFA Lugano Financial Advisors SA boosted its holdings in shares of Abbott Laboratories by 7.6% in the 1st quarter. LFA Lugano Financial Advisors SA now owns 2,525 shares of the healthcare product maker’s stock valued at $335,000 after acquiring an additional 178 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $124.42 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company’s fifty day moving average price is $131.78 and its 200 day moving average price is $131.64. The company has a market capitalization of $216.55 billion, a PE ratio of 15.59, a price-to-earnings-growth ratio of 2.40 and a beta of 0.69. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. The company had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a report on Thursday, October 16th. Evercore ISI lowered their price target on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a report on Wednesday, October 15th. Finally, Raymond James Financial increased their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $147.00.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.